CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Choosing a total market fund for a Roth IRA doesn't have to be hard. Compare options, fees, and diversification to build a solid retirement strategy.
28,468 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
As AI accelerates, investors face a long-term choice between NVDA and AMD. This piece weighs profitability, growth, a...
As Nvidia powers AI breakthroughs and data centers expand, silver’s role in electronics could rise. This guide breaks...
Not all tech stocks pay dividends, but a small group do. Here are two reliable picks that blend growth with income, p...
As Greg Abel steers Berkshire Hathaway's non-insurance businesses, Berkshire Hathaway Energy could emerge as a reliab...
When SpaceX surged, several smaller space stocks fell hard. Was it just rotation, or a signal to rethink the sector? ...
Robinhood stock soared from its spring lows, delivering a eye-catching rally. But a deeper look at revenue mix, regul...
The AI hardware boom is fading as demand cools, dragging optical and memory stocks lower and prompting investors to r...
Pipelines may not grab headlines, but their steady cash flow powers dividends for investors who plan ahead. Learn how...
A bold IPO from Quantinuum has lit a new phase for quantum stocks. As quantinuum's putting pressure ionq, investors n...
Prices for gold and silver swung recently, and SSR Mining stock moved with them. This guide breaks down whether you s...
Two top physical silver ETFs face off as 2026 volatility tests liquidity and cost. This report breaks down which is s...